ALEXION PHARMACEUTICALS INC

(Street)

Form 4

August 16, 2013

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading **BELL LEONARD** Issuer Symbol ALEXION PHARMACEUTICALS (Check all applicable) INC [ALXN] (Last) (First) (Middle) 3. Date of Earliest Transaction _X__ Director 10% Owner _ Other (specify X_ Officer (give title (Month/Day/Year) below) below) C/O ALEXION 08/15/2013 CEO PHARMACEUTICALS INC, 352 KNOTTER DRIVE

4. If Amendment, Date Original

Filed(Month/Day/Year)

CHESHIRE, CT 06410

Form filed by More than One Reporting Person

Applicable Line)

6. Individual or Joint/Group Filing(Check

X Form filed by One Reporting Person

| (City) | (State) | (Zip) Tab | le I - Non-I | Derivative | Secur | ities Acqui | red, Disposed of, | or Beneficial | ly Owned |
|---|--------------------------------------|---|--|------------------------------------|---------|---------------------|--|--|---|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transactic Code (Instr. 8) | 4. Securit or Dispos (Instr. 3, 4) | ed of (| ` ′ | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Common Stock, par value \$.0001 per share | 08/15/2013 | | | | ` ´ | | 1,147,495 | D | |
| Common Stock, par value \$.0001 per share | 08/15/2013 | | S | 56,278 (1) | D | \$ 106.36 (3) | 1,091,217 | D | |

OMB APPROVAL

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

| Common Stock, par value \$.0001 per share | 08/16/2013 | S | 24,624 (1) | D | \$ 105.58 (4) | 1,066,593 | D |
|---|------------|---|---------------|---|---------------------|-----------|---|
| Common Stock, par value \$.0001 per share | 08/16/2013 | S | 29,924 (1) | D | \$ 104.97 (5) | 1,036,669 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secu Bene Own Follo Repo Trans (Insti

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of | 2. | 3. Transaction Date | 3A. Deemed | 4. | 5. | 6. Date Exerc | isable and | 7. Title | and | 8. Price of | • |
|-------------|-------------|---------------------|--------------------|-----------|--------------|---------------|------------|-----------|----------|-------------|-----|
| Derivative | Conversion | (Month/Day/Year) | Execution Date, if | Transac | tionNumber | Expiration Da | ite | Amoun | t of | Derivative | ļ |
| Security | or Exercise | | any | Code | of | (Month/Day/ | Year) | Underly | ying | Security | |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. 8 |) Derivative | e | | Securit | ies | (Instr. 5) | 1 |
| | Derivative | | | | Securities | 3 | | (Instr. 3 | 3 and 4) | | |
| | Security | | | | Acquired | | | | | | . 1 |
| | • | | | | (A) or | | | | | | 1 |
| | | | | | Disposed | | | | | | |
| | | | | | of (D) | | | | | | |
| | | | | | (Instr. 3, | | | | | | |
| | | | | | 4, and 5) | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | Amount | | |
| | | | | | | Date | Expiration | | or | | |
| | | | | | | | Date | | Number | | |
| | | | | | | | | | of | | |
| | | | | Code ' | V (A) (D) | | | | Shares | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | |
|--|---------------|-----------|---------|-------|--|--|
| | Director | 10% Owner | Officer | Other | | |
| BELL LEONARD C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE CHESHIRE, CT 06410 | X | | CEO | | | |

Signatures

/s/ Leonard Bell 08/16/2013 **Signature of Date Reporting Person

2 Reporting Owners

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$106.79 \$107.79. The price reported in (2) this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$105.79 \$106.79. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$105.26 \$106.26. The price reported in (4) this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$104.26 \$105.26. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.